Feline infectious peritonitis (FIP) is caused by a mutated form of a common feline coronavirus, and until recently it was considered a death sentence for any cat that developed it. That has changed dramatically. An antiviral drug called GS-441524, first tested in cats in 2018, now achieves survival rates above 80% in treated cats, with some studies reporting even higher figures. The transformation from universally fatal disease to treatable condition has happened remarkably fast, though the path has involved black-market drug purchases, regulatory gaps, and a scientific story that is still being written.
How a Common Virus Turns Deadly
Most cats that encounter feline coronavirus (FCoV) never get seriously ill. The standard form of the virus, called feline enteric coronavirus (FECV), infects cells lining the intestinal tract and typically causes nothing worse than mild, self-limiting diarrhea. Many cats shed the virus without any symptoms at all. Estimates suggest that the vast majority of purebred cats and a large share of mixed-breed cats have been exposed to FCoV at some point, especially those in multi-cat environments like shelters, catteries, and breeding colonies.
FIP develops when the virus mutates inside an individual cat. These mutations give the virus a new ability: instead of replicating only in gut cells, the altered virus can infect and replicate inside macrophages, a type of white blood cell that normally helps fight infections. Once the virus hijacks macrophages, it essentially catches a ride through the cat’s bloodstream, spreading rapidly to organs throughout the body.1PubMed Central. Acquisition of macrophage tropism during the pathogenesis of feline infectious peritonitis is determined by mutations in the feline coronavirus spike protein The specific mutations involved appear to occur in the spike protein on the surface of the virus, though researchers have not identified a single consistent genetic marker that distinguishes harmless FCoV from the lethal FIP-causing form in every case.2PubMed Central. Spike protein fusion peptide and feline coronavirus virulence
This mutation happens inside the individual cat, which is an important distinction. FIP is not typically spread from cat to cat as FIP. One cat in a household developing FIP does not mean the other cats will also get it, though all cats in the household may carry the underlying enteric coronavirus. Of cats infected with FCoV, roughly 5 to 12% go on to develop clinical FIP.3PubMed Central. Feline infectious peritonitis: A comprehensive evaluation of clinical manifestations, laboratory diagnosis, and therapeutic approaches Why some cats’ immune systems contain the virus while others allow the fatal mutation to take hold is a question researchers are still working to fully answer, though both the cat’s immune response and genetic background play roles.
Which Cats Are Most at Risk
FIP tends to strike young cats. Most cases occur in cats under two years old, with a particular concentration in kittens and adolescent cats whose immune systems are still maturing. Males appear to be diagnosed more frequently than females, and sexually intact cats are more likely to develop FIP than those that have been spayed or neutered.4PubMed Central. Prevalence of feline infectious peritonitis in specific cat breeds
Breed matters too, though the picture is more nuanced than simply “purebreds are at higher risk.” While purebred cats as a group do face elevated risk, specific breeds carry particularly high susceptibility. Abyssinians, Bengals, Birmans, Himalayans, Ragdolls, and Rex breeds all show significantly higher rates of FIP. Interestingly, several other purebred lines, including Burmese, Exotic Shorthairs, Persians, Russian Blues, and Siamese, do not show an increased risk compared to mixed-breed cats.4PubMed Central. Prevalence of feline infectious peritonitis in specific cat breeds Researchers have conducted genome-wide studies in Birman cats looking for genetic susceptibility, and identified several candidate genes that could influence whether a cat’s immune system successfully contains the virus or allows it to progress to FIP.5PubMed Central. Genetic susceptibility to feline infectious peritonitis in Birman cats No single gene explains the disease, but the research suggests that FIP susceptibility has a real genetic component, particularly in highly inbred lines.
Stress also appears to be a trigger. Cats in shelters, those recently adopted into new homes, cats that have just been neutered, or those dealing with overcrowded living situations seem to develop FIP at higher rates. The working theory is that stress suppresses the immune system just enough to allow the mutated virus to gain a foothold.
Wet Form Versus Dry Form
FIP shows up in two broad patterns, often called the “wet” (effusive) and “dry” (non-effusive) forms, though many cats present with features of both. The distinction matters because the forms look quite different clinically, and the wet form is generally easier to recognize.
In wet FIP, fluid accumulates in the abdomen, the chest cavity, or both. A kitten with a swollen, fluid-filled belly is one of the most recognizable presentations. The fluid itself is characteristic: it tends to be yellowish and straw-colored, sticky, and protein-rich. Analysis of this effusion typically shows high protein levels and inflammatory cells.3PubMed Central. Feline infectious peritonitis: A comprehensive evaluation of clinical manifestations, laboratory diagnosis, and therapeutic approaches When fluid accumulates in the chest, cats may struggle to breathe rather than showing abdominal swelling.
Dry FIP is harder to pin down. Instead of fluid accumulation, the disease creates inflammatory lesions called granulomas in various organs. These can appear in the kidneys, liver, lymph nodes, eyes, and brain. Because the symptoms depend entirely on which organs are affected, dry FIP can mimic many other diseases. A cat with kidney granulomas might show weight loss and poor appetite. A cat with eye involvement might develop cloudiness in the iris or unusual changes in pupil appearance. When the brain or spinal cord is affected, symptoms can include seizures, wobbliness, behavioral changes, and difficulty walking.6PubMed Central. Diagnosis and clinical signs of feline infectious peritonitis in the central nervous system
Regardless of form, most cats with FIP develop a persistent fever that does not respond to antibiotics, progressive weight loss, and lethargy. These nonspecific signs, combined with the young age of most affected cats, are often what first prompts a veterinary visit.
Why Diagnosing FIP Is So Difficult
There is no single, simple test for FIP, and this remains one of the most frustrating aspects of the disease. Antibody tests for feline coronavirus are widely available, but they cannot distinguish between a cat that has been harmlessly exposed to the common enteric form and one whose virus has mutated into the lethal form. Given how widespread FCoV exposure is, a positive antibody test alone means very little.
In practice, diagnosis relies on pulling together multiple lines of evidence: the cat’s history, age, breed, clinical signs, bloodwork abnormalities, imaging findings, and analysis of any effusion present. Abdominal ultrasound can reveal fluid accumulation, organ changes, and enlarged lymph nodes. When fluid is available, its protein content, cell types, and the ratio of albumin to globulin help build the case. Molecular testing using RT-PCR on fluid or tissue samples and immunohistochemistry on biopsies can detect the virus directly and provide stronger confirmation.7SAGE Journals (PubMed Central). Abdominal ultrasonographic findings of cats with feline infectious peritonitis: an update
The wet form is generally easier to diagnose because the effusion provides material to test. The dry form can require biopsy of affected organs before a confident diagnosis is reached, which is not always practical in a sick cat. Veterinarians often have to make a “highly probable” diagnosis based on the weight of clinical evidence and begin treatment on that basis, refining the diagnosis as the cat’s response to treatment provides further information.
GS-441524 Changed Everything
Before antiviral treatments, FIP was invariably fatal. Cats diagnosed with FIP were given supportive care and eventually euthanized. The arrival of GS-441524 completely rewrote that prognosis. The drug is a nucleoside analog that works by interfering with the virus’s ability to copy its genetic material. When the virus tries to replicate its RNA, GS-441524 gets incorporated into the growing chain and stops it.8PubMed Central. The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis virus in tissue culture and experimental cat infection studies
The first landmark study, published in 2019, treated 26 cats with naturally occurring FIP. Of those, 25 became long-term survivors after one or more rounds of treatment. Cats that relapsed after an initial course responded to retreatment at higher doses, including one cat with neurological disease.9PubMed Central. Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis For a disease that had been 100% fatal, these results were extraordinary.
Since then, the evidence base has grown substantially. A systematic review covering 11 studies and 650 FIP cases treated with GS-441524 found an overall treatment success rate of about 85%.10PubMed Central. Efficacy of GS-441524 for Feline Infectious Peritonitis: A Systematic Review (2018-2024) A larger study analyzing over 600 cats reported an even higher cure rate of about 94%.11Scientific Reports. Analysis of risk factors, clinical data, treatment outcomes for cats with feline infectious peritonitis using GS-441524 (2020–2024) These numbers vary somewhat depending on the form of FIP and whether the brain or eyes are involved, but the overall picture is unmistakable: a disease with zero percent survival now has survival rates that would be enviable for many human cancers.
How Treatment Typically Works
Standard GS-441524 treatment runs for about 12 weeks, though the exact duration depends on the form and severity of FIP. The drug can be given as an injection under the skin or as oral tablets. Many protocols start with injectable remdesivir (a closely related prodrug that the body converts into GS-441524) and transition to oral GS-441524 once the cat stabilizes. A large retrospective study of 307 cats found that legally sourced remdesivir and GS-441524 products, used either alone or in sequence, were very effective.12PubMed Central. Retrospective study and outcome of 307 cats with feline infectious peritonitis treated with legally sourced veterinary compounded preparations of remdesivir and GS-441524 (2020-2022)
During treatment, veterinarians monitor blood markers to track the cat’s response. Acute phase proteins, particularly serum amyloid A (SAA) and alpha-1 acid glycoprotein (α1AG), appear to be useful indicators for gauging when treatment can safely be stopped.13PubMed Central. High-dose induction therapy and treatment termination criteria for feline infectious peritonitis with remdesivir and GS-441524 These inflammatory markers drop as the virus is brought under control, and their normalization helps veterinarians decide whether to continue or discontinue therapy rather than relying purely on a fixed calendar duration.
Relapse is possible. Some cats show signs of recurring disease during or after treatment, which could reflect antiviral resistance, differences in how the drug distributes through the body, the initial viral load, or characteristics of the virus strain involved.14Journal of Veterinary Internal Medicine. Outcomes of treatment of cats with feline infectious peritonitis using parenterally administered remdesivir, with or without transition to orally administered GS-441524 In those cases, retreatment at a higher dose often succeeds, and the overall prognosis remains favorable even for cats that need a second course.
Neurological and Ocular FIP Requires Extra Attention
Not all forms of FIP respond equally well to treatment. When the disease involves the brain or eyes, treatment becomes more complicated because the blood-brain barrier and blood-ocular barrier limit how much drug reaches those sites.15Journal of Veterinary Internal Medicine. Antiviral treatment using the adenosine nucleoside analogue GS-441524 in cats with clinically diagnosed neurological feline infectious peritonitis Cats with neurological FIP, those showing seizures, head tilts, difficulty walking, or behavioral changes, typically require higher doses and sometimes longer treatment courses.
Ocular FIP, which can present as inflammation inside the eye, cloudy fluid in the front chamber, or changes in iris color and texture, poses similar challenges. Early in the GS-441524 research, there was concern that these forms might prove resistant to treatment. While they do require more aggressive dosing, successful treatment is still possible. The initial 2019 study included a cat with neurological FIP that responded to retreatment at a higher dose, and subsequent clinical experience has expanded the toolkit for managing these more difficult presentations.
If your cat is showing neurological or eye symptoms alongside the more common signs of FIP, it is worth seeking a veterinarian experienced with antiviral FIP treatment. The dosing and monitoring considerations are different enough from standard effusive FIP that expertise matters.
Other Antivirals in the Mix
GS-441524 is the most studied treatment, but it is not the only antiviral being explored for FIP. Two other drugs deserve mention.
Molnupiravir, another antiviral originally developed for human use, has shown promise in a case series of 18 cats. Of those, 14 achieved remission without relapse during follow-up, though four cats with the effusive form died within the first week of treatment.16PubMed Central. Molnupiravir treatment of 18 cats with feline infectious peritonitis: A case series Molnupiravir works through a different mechanism than GS-441524. Rather than stopping the viral RNA chain, it introduces copying errors into the viral genome during replication, eventually making the virus non-functional. The early losses in that study may reflect how sick the cats were at treatment start rather than a fundamental limitation of the drug, but the evidence base is still thin compared to GS-441524.
GC376, a protease inhibitor, targets a different viral enzyme altogether. Instead of interfering with RNA copying, it blocks the viral protease that the virus needs to process its proteins into functional forms. Laboratory and early animal studies showed GC376 could effectively reduce viral loads in macrophages taken from cats with FIP.17PLOS Pathogens. Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor Having antivirals that attack the virus at different points is potentially valuable, especially for cases that do not respond to GS-441524 alone or for possible combination therapy approaches in the future.
The Black Market Era and the Regulatory Catch-Up
The story of FIP treatment cannot be told without acknowledging the strange regulatory limbo that defined its early years. GS-441524 was developed by Gilead Sciences, the same company behind remdesivir (used against COVID-19 in humans). After the initial research proved the drug worked in cats, it stalled in the development pipeline. No licensed veterinary product was made available, and Gilead did not immediately pursue veterinary approval.
Cat owners, faced with a fatal diagnosis and an effective drug that simply was not available through legitimate channels, turned to the internet. Online communities sprang up on social media platforms, connecting owners with sources of unlicensed GS-441524 manufactured overseas.18PubMed Central. Owner experience and veterinary involvement with unlicensed GS-441524 treatment of feline infectious peritonitis: a prospective cohort study These “citizen scientist” networks coached owners through treatment protocols, dosing calculations, and monitoring, sometimes with minimal veterinary involvement. The drugs, often shipped from China, came in unmarked vials with uncertain purity, and prices ran into the thousands of dollars for a full treatment course.
This situation put veterinarians in an uncomfortable position. Many knew the drug worked but could not legally prescribe it. Some quietly supported owners who sourced the drug independently. Others worried about the risks of unregulated products with unknown composition and inconsistent potency. The tension between medical ethics, regulatory compliance, and a desperate clinical need was real and widely discussed in the veterinary community.
The landscape has been shifting. Legally sourced veterinary compounded preparations of both remdesivir and GS-441524 have become available in some countries, and studies using these regulated products have confirmed their effectiveness.12PubMed Central. Retrospective study and outcome of 307 cats with feline infectious peritonitis treated with legally sourced veterinary compounded preparations of remdesivir and GS-441524 (2020-2022) In 2024, the first formally approved GS-441524 product for cats received regulatory clearance in some markets. The situation continues to evolve, and access still varies significantly by country, but the trajectory is toward legitimate, quality-controlled products replacing the black-market supply chain.
What Treatment Actually Costs
Cost remains a real barrier for many cat owners. A full 12-week course of GS-441524 can be expensive, particularly when you factor in the drug itself, the diagnostic workup, follow-up bloodwork and monitoring visits, and any complications along the way. Neurological cases requiring higher doses cost more. Injectable formulations tend to be pricier than oral tablets but may be necessary early in treatment when a cat is too sick to take pills reliably.
Prices have come down from the early black-market days, when a course of treatment could easily run $5,000 to $10,000 or more depending on the cat’s weight and the severity of disease. As legal products enter the market and competition increases, costs are expected to continue decreasing, though FIP treatment is unlikely to become cheap. Some veterinary schools and referral hospitals have begun offering treatment at more accessible price points, and a few charitable organizations now help subsidize treatment costs for qualifying owners.
If cost is a concern, it is worth discussing openly with your veterinarian early. There may be options to manage expenses, such as using oral formulations when clinically appropriate, adjusting monitoring frequency based on how the cat is responding, or seeking out clinical trials that cover part of the treatment cost.
Living After FIP
Cats that successfully complete treatment generally go on to live normal lives. The virus is cleared, and there is no evidence of chronic organ damage in most survivors, though cats that had severe disease may have some residual effects depending on which organs were involved. Post-treatment monitoring typically involves periodic bloodwork over several months to watch for relapse, particularly in the first three months after stopping the drug.
One question owners frequently ask is whether a cat that has had FIP can live safely with other cats. Since FIP itself develops from an internal mutation and is not typically transmitted in its virulent form between cats, there is no strong reason to isolate a recovered cat from housemates. The underlying feline coronavirus can spread between cats, but that is true of most multi-cat households anyway, and exposure to FCoV does not mean FIP will follow.
Vaccination is another topic that comes up. A modified live intranasal FCoV vaccine exists, but its efficacy has been debated for decades, and it is not widely used or recommended by major veterinary organizations. The vaccine works by stimulating local immunity in the nasal passages and upper respiratory tract, but since the natural entry point for FCoV is typically the gastrointestinal tract, the relevance of upper respiratory immunity is questionable. Most veterinary guidelines consider FIP prevention to be better achieved through good husbandry practices in multi-cat environments, including reducing overcrowding, keeping litter boxes clean, and minimizing stress, rather than through vaccination.
For breeders of high-risk breeds like Birmans, Bengals, and Ragdolls, the genetic component of susceptibility adds another layer. While no genetic test currently predicts FIP risk in individual cats, breeders who have had multiple FIP cases in their lines may benefit from consulting with veterinary geneticists about breeding decisions. The identification of candidate susceptibility genes in breeds like the Birman represents early steps toward understanding which cats are most vulnerable, but practical breeding tools based on this research are still in the future.5PubMed Central. Genetic susceptibility to feline infectious peritonitis in Birman cats